Chromosome band 17q21 in breast cancer

Significant association between beclin 1 loss and HER2/NEU amplification

Tiziana Negri, Eva Tarantino, Marta Orsenigo, James F. Reid, Manuela Gariboldi, Milvia Zambetti, Marco A. Pierotti, Silvana Pilotti

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Treatment success of breast cancer patients with trastuzumab alone or in combination depends not only on HER2/NEU amplification but also on PTEN and PI3K status and efficient cell death programs. In this pilot study, we found a significant association between loss of beclin 1 and HER2/NEU amplification (both on 17q21) in breast cancers. This finding was confirmed in two public copy number microarray datasets. Furthermore, there is a trend associating beclin 1 loss with TP53 mutations, PI3KCA gene gain, and PTEN mutations. Finally, the observation that beclin 1 gene loss predicted a response to trastuzumab alone or in combination with other drugs is worthy of further confirmation in larger cohorts. Our results suggest that, beclin 1 loss may contribute to genome instability and to a defective autophagy that may lead to tumoral cell death in presence of competent apoptosis or senescence pathways.

Original languageEnglish
Pages (from-to)901-909
Number of pages9
JournalGenes Chromosomes and Cancer
Volume49
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Chromosomes
Breast Neoplasms
Cell Death
Mutation
Genomic Instability
Autophagy
Phosphatidylinositol 3-Kinases
Genes
Apoptosis
Beclin-1
Pharmaceutical Preparations
Trastuzumab
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Chromosome band 17q21 in breast cancer : Significant association between beclin 1 loss and HER2/NEU amplification. / Negri, Tiziana; Tarantino, Eva; Orsenigo, Marta; Reid, James F.; Gariboldi, Manuela; Zambetti, Milvia; Pierotti, Marco A.; Pilotti, Silvana.

In: Genes Chromosomes and Cancer, Vol. 49, No. 10, 10.2010, p. 901-909.

Research output: Contribution to journalArticle

Negri, T, Tarantino, E, Orsenigo, M, Reid, JF, Gariboldi, M, Zambetti, M, Pierotti, MA & Pilotti, S 2010, 'Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification', Genes Chromosomes and Cancer, vol. 49, no. 10, pp. 901-909. https://doi.org/10.1002/gcc.20798
Negri, Tiziana ; Tarantino, Eva ; Orsenigo, Marta ; Reid, James F. ; Gariboldi, Manuela ; Zambetti, Milvia ; Pierotti, Marco A. ; Pilotti, Silvana. / Chromosome band 17q21 in breast cancer : Significant association between beclin 1 loss and HER2/NEU amplification. In: Genes Chromosomes and Cancer. 2010 ; Vol. 49, No. 10. pp. 901-909.
@article{92e97bbdb98a4e8483251b40c0e05525,
title = "Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification",
abstract = "Treatment success of breast cancer patients with trastuzumab alone or in combination depends not only on HER2/NEU amplification but also on PTEN and PI3K status and efficient cell death programs. In this pilot study, we found a significant association between loss of beclin 1 and HER2/NEU amplification (both on 17q21) in breast cancers. This finding was confirmed in two public copy number microarray datasets. Furthermore, there is a trend associating beclin 1 loss with TP53 mutations, PI3KCA gene gain, and PTEN mutations. Finally, the observation that beclin 1 gene loss predicted a response to trastuzumab alone or in combination with other drugs is worthy of further confirmation in larger cohorts. Our results suggest that, beclin 1 loss may contribute to genome instability and to a defective autophagy that may lead to tumoral cell death in presence of competent apoptosis or senescence pathways.",
author = "Tiziana Negri and Eva Tarantino and Marta Orsenigo and Reid, {James F.} and Manuela Gariboldi and Milvia Zambetti and Pierotti, {Marco A.} and Silvana Pilotti",
year = "2010",
month = "10",
doi = "10.1002/gcc.20798",
language = "English",
volume = "49",
pages = "901--909",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Chromosome band 17q21 in breast cancer

T2 - Significant association between beclin 1 loss and HER2/NEU amplification

AU - Negri, Tiziana

AU - Tarantino, Eva

AU - Orsenigo, Marta

AU - Reid, James F.

AU - Gariboldi, Manuela

AU - Zambetti, Milvia

AU - Pierotti, Marco A.

AU - Pilotti, Silvana

PY - 2010/10

Y1 - 2010/10

N2 - Treatment success of breast cancer patients with trastuzumab alone or in combination depends not only on HER2/NEU amplification but also on PTEN and PI3K status and efficient cell death programs. In this pilot study, we found a significant association between loss of beclin 1 and HER2/NEU amplification (both on 17q21) in breast cancers. This finding was confirmed in two public copy number microarray datasets. Furthermore, there is a trend associating beclin 1 loss with TP53 mutations, PI3KCA gene gain, and PTEN mutations. Finally, the observation that beclin 1 gene loss predicted a response to trastuzumab alone or in combination with other drugs is worthy of further confirmation in larger cohorts. Our results suggest that, beclin 1 loss may contribute to genome instability and to a defective autophagy that may lead to tumoral cell death in presence of competent apoptosis or senescence pathways.

AB - Treatment success of breast cancer patients with trastuzumab alone or in combination depends not only on HER2/NEU amplification but also on PTEN and PI3K status and efficient cell death programs. In this pilot study, we found a significant association between loss of beclin 1 and HER2/NEU amplification (both on 17q21) in breast cancers. This finding was confirmed in two public copy number microarray datasets. Furthermore, there is a trend associating beclin 1 loss with TP53 mutations, PI3KCA gene gain, and PTEN mutations. Finally, the observation that beclin 1 gene loss predicted a response to trastuzumab alone or in combination with other drugs is worthy of further confirmation in larger cohorts. Our results suggest that, beclin 1 loss may contribute to genome instability and to a defective autophagy that may lead to tumoral cell death in presence of competent apoptosis or senescence pathways.

UR - http://www.scopus.com/inward/record.url?scp=77957861637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957861637&partnerID=8YFLogxK

U2 - 10.1002/gcc.20798

DO - 10.1002/gcc.20798

M3 - Article

VL - 49

SP - 901

EP - 909

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 10

ER -